Opportunistic Neurologic Infections With CD3-Engaging Bispecific Antibodies in Hematologic Malignancies: A FAERS Disproportionality Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #MM-1497; Location: LEVEL 3, HALL B3; "Interventions: Included agents were teclistamab, elranatamab, talquetamab, linvoseltamab, blinatumomab, mosunetuzumab, epcoritamab, and glofitamab. In FAERS, CD3-engaging bispecific antibodies showed strong pharmacovigilance signals for opportunistic neurologic infections, predominantly progressive multifocal leukoencephalopathy/JC virus events, with the most consistent signals observed for BCMA-directed agents. FAERS signals do not establish incidence or causality, but surveillance for opportunistic CNS infections should be considered in postmarketing safety frameworks for bispecific antibodies. AIDS: acquired immunodeficiency syndrome, BCMA: B-cell maturation antigen, CAR-T: chimeric antigen receptor T-cell, CD: cluster of differentiation, FDA: US Food and Drug Administration, HIV: human immunodeficiency virus, JC: John Cunningham, MM: multiple myeloma, OR: odds ratio."
Bispecific • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin's Lymphoma • Oncology • CD20
|
|
Büsranur Yilmaz MD 1,2; Alina Tariq MD 3; Tamara Hossein 4; Fatmanur Yilmaz MD 5; Bailey Grones 6
|